Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TNKS | O95271 | 1/20 | 0.35 |
| ▸ | HTR1D | P28221 | 1/20 | 0.31 |
| ▸ | HTR1B | P28222 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5180793 | 0.82 | AR (0.32) | — | |
| SCHEMBL5181473 | 0.78 | PTPN2 (0.33) | — | |
| SCHEMBL5182190 | 0.78 | AR (0.32) | — | |
| SCHEMBL5183149 | 0.77 | PPARG (0.36) | KMT2A | |
| SCHEMBL5182621 | 0.76 | HRH3 (0.37) | HRH3 | |
| SCHEMBL5181018 | 0.75 | MEN1 (0.34) | HRH3KMT2A | |
| SCHEMBL5184166 | 0.72 | ALDH1A1 (0.39) | HRH3 | |
| SCHEMBL5181022 | 0.72 | ALDH1A1 (0.39) | HRH3 | |
| SCHEMBL5181857 | 0.72 | AR (0.32) | — | |
| SCHEMBL5183995 | 0.71 | HRH3 (0.31) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1366025-B1 | AGONISTS OF BETA-ADRENORECEPTORS | GLAXO GROUP LTD (GB) | 2007-06-27 | — | — | EP | disclosed |
| US-7144908-B2 | Agonists of beta-adrenoceptors | GLAXO GROUP LIMITED (GB) | 2006-12-05 | — | — | US | disclosed |
| US-20040242890-A1 | Agonists of beta-adrenoceptors | GLAXO GROUP LIMITED (GB) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242890-A1 | Agonists of beta-adrenoceptors | ADRB1, ADRB2, ADRA1A | GSK3A 1844/4885GSK3B 1799/4885HRH3 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.